NEW YORK (GenomeWeb News) - Thermo Fisher Scientific today reported a 12 percent drop in first-quarter revenues and a 35 percent fall in net profit as it lowered its guidance for full-year 2009 by $400 million.

"The tough economy had a significant impact on our results for the first quarter, particularly in our instrumentation and equipment businesses," Marijn Dekkers, president and CEO of the company, said in a statement. "Our customers are clearly delaying their capital purchases in the current environment."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.